Navigation Links
Therapeutic Area Essentials "Class of 2011" Brings Current Disease State Training to Pharma
Date:6/20/2011

RALEIGH, N.C., June 20, 2011 /PRNewswire/ -- Pharmaceutical Institute, the leading provider of specialized training solutions for the pharmaceutical and biotech industry and a subsidiary of Campbell Alliance, announced today the completion of 2011 updates to its Therapeutic Area Essentials™ e-course series.  This series delivers in-depth disease state training for pharmaceutical and biotech R&D and commercial professionals.  It includes 155 e-courses covering the diagnosis, cause, and treatment for more than 45 disease states.

Therapeutic Area Essentials™ provides the pharmaceutical and biotech industry with a single source for current and comprehensive disease state training.  All courses have been updated in 2011 by Pharmaceutical Institute's content scientists and physician experts.  Updates reflect the most current disease state knowledge such as prevalence and incidence statistics, disease understanding (including cause, risk factors, and progression), diagnostic procedures, and treatment guidelines.  

"Providing pharma and biotech employees with immediate, needs-based access to high quality disease state training can deliver significant value," says Garry O'Grady, Senior Vice President and General Manager of Pharmaceutical Institute.  "We're pleased to provide a go-to resource for high-quality training content across the therapeutic area spectrum."

Core therapeutic areas covered by Therapeutic Area Essentials™ include cardiology and metabolic disorders, gastroenterology, infections, musculoskeletal, neurology, oncology, ophthalmology, and respiratory disorders.  The series also provides anatomy and physiology training for each of these systems.

For more information on the Therapeutic Area Essentials™ training solutions, including a complete list of courses, please visit:

SOURCE Pharmaceutical Institute
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6
2. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
3. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
4. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
5. Cardinal Health, Prime Therapeutics Renew Primary Distribution Agreement
6. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
7. Cell Therapeutics Completes Type A Meeting With FDAs Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
8. Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices
9. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
10. Grifols Announces Combined Operations With Talecris to Begin a New Era as a Global Leader of Life-Saving Plasma Therapeutics
11. Healthpoint Biotherapeutics to Present at Upcoming Investment Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" report ... was approved by CFDA to treat wet age- related ... product of Novartis, is available in the Chinese market. ... drug for the treatment of wet AMD in ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Inc. (DCI), announced that the company has received ... its New Drug Application (NDA) for PERTZYE™, indicated ... due to cystic fibrosis (CF) or other conditions.  ... enzyme product containing bicarbonate-buffered enteric-coated microspheres and is ...
... Inc. today announced that company personnel will deliver a ... Week (DDW) annual meeting at 9 a.m. PDT on ... Center in San Diego, California. DDW attracts thousands of ... share the latest research in gastrointestinal health topics, for ...
Cached Medicine Technology:Digestive Care, Inc. Announces FDA Approval of PERTZYE™ (pancrelipase) Delayed-Release Capsules 2Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease 2
(Date:8/31/2015)... ... 31, 2015 , ... Intellitec Solutions announced they have reached a record for ... new staff member in 2015. With the potential for more hiring occurring before the ... Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, and has hired new support staff ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... California (PRWEB) , ... August 31, 2015 , ... Avid ... Morrison and the Doors Shrine Auditorium concert posters. This hand colored artwork is one ... and 23 in Los Angles. Hawley states, "When the doors played the Shrine, ...
(Date:8/30/2015)... ... 2015 , ... ChopChop Kids, the nonprofit publisher of the ... two new officers to serve on the organization’s Board of Directors in accordance ... kids to cook real food with their families and help continue to drive ...
(Date:8/30/2015)... ... ... Scientists in France say asbestos exposure may put workers at higher risk ... just posted an article on the new research. Click here to read it ... 2,024 French asbestos plant workers from 1978 to 2009. In addition to mesothelioma, the ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2
... in as the 5th Chair on "The Doctors", LOS ... be the guest co-host on the number one new syndicated,talk ... (check local,listings, http://www.thedoctorstv.com )., Best known from the ... York Times Bestselling Author for his book, Billion Dollar Smile,sits ...
... fatal parasite; first vaccines delivered following major funding award. ... that could eradicate a fatal form of brain disease ... soon be commercially available thanks to multi-million dollar funding. ... million tapeworm infections and 50,000 deaths from brain disease ...
... Abbott (NYSE: ABT ),will present at the 17th ... Thomas C. Freyman, executive vice president, finance,and chief financial ... 5,p.m. CST., A live audio webcast of the ... at http://www.abbottinvestor.com . An,archived edition of the presentation ...
... for stroke ... treatment, ... a team,of stroke experts from the West Virginia University Health Sciences ... The study showed CT perfusion had,100 percent accuracy for detecting the ...
... of America, Inc.,(OTC Bulletin Board: CPCF), a company ... in endovascular procedures, today announced,that it is implementing ... its MedClose(TM) investigational-stage medical device. In,the roll out ... Medical,Product Service GmbH (MPS) of Germany to act ...
... Emergency Room Life Through Eyes of Poet Doctor, ... care,crisis in America to the natural fear of illness ... wonder and poetry in medical practice.,Bertrand P. Fote has ... his,work as an emergency physician, and he captures this ...
Cached Medicine News:Health News:Celebrity Cosmetic Dentist to Guest Co-Host New National Day Time Talk Show 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 3Health News:West VA University Study Calls for New Method of Stroke Diagnosis 2Health News:West VA University Study Calls for New Method of Stroke Diagnosis 3Health News:West VA University Study Calls for New Method of Stroke Diagnosis 4Health News:CPC Appoints Medical Product Service GmbH as Authorized European Representative for MedClose(TM) System 2Health News:CPC Appoints Medical Product Service GmbH as Authorized European Representative for MedClose(TM) System 3Health News:Physician Portrays Powerful Poetry at Heart of Human Condition 2
Trans-Blot Plus Gel/Cassette Assembly Tray...
Ice block will provide sufficient cooling for most normal blotting applications. Sealed block is held submerged in transfer buffer. Ice block will not spill during refreezing....
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Advantages of using the Antigen-Antibody Pens-Using a ... and developed specialized fountain pens, called Antigen-Antibody ... or write/mark the blotting membranes in any ... formulated antigen-bonded colored dyes helps to see ...
Medicine Products: